Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-120 Nasal Spray in Asymptomatic or Mild COVID-19
NCT05659602Completed
- Sponsor
- Beijing Ditan Hospital
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of HH-120 in coronavirus disease 2019 (COVID-19), sponsored by Beijing Ditan Hospital. Primary endpoints: Time to achieving SARS-CoV-2 clearance up to 12 days and Proportion of participants with SARS-CoV-2 clearance up to 12 days. Started Jul 2022; status: completed.
02
Drugs
HH-120
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05659602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659602.